857 related articles for article (PubMed ID: 20566620)
1. Postmenopausal hormone therapy: an Endocrine Society scientific statement.
Santen RJ; Allred DC; Ardoin SP; Archer DF; Boyd N; Braunstein GD; Burger HG; Colditz GA; Davis SR; Gambacciani M; Gower BA; Henderson VW; Jarjour WN; Karas RH; Kleerekoper M; Lobo RA; Manson JE; Marsden J; Martin KA; Martin L; Pinkerton JV; Rubinow DR; Teede H; Thiboutot DM; Utian WH;
J Clin Endocrinol Metab; 2010 Jul; 95(7 Suppl 1):s1-s66. PubMed ID: 20566620
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.
Stuenkel CA; Davis SR; Gompel A; Lumsden MA; Murad MH; Pinkerton JV; Santen RJ
J Clin Endocrinol Metab; 2015 Nov; 100(11):3975-4011. PubMed ID: 26444994
[TBL] [Abstract][Full Text] [Related]
4. Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement.
Golden SH; Brown A; Cauley JA; Chin MH; Gary-Webb TL; Kim C; Sosa JA; Sumner AE; Anton B
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1579-639. PubMed ID: 22730516
[TBL] [Abstract][Full Text] [Related]
5. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
Cobin RH; Goodman NF;
Endocr Pract; 2017 Jul; 23(7):869-880. PubMed ID: 28703650
[TBL] [Abstract][Full Text] [Related]
6. Long-term hormone therapy for perimenopausal and postmenopausal women.
Marjoribanks J; Farquhar C; Roberts H; Lethaby A; Lee J
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004143. PubMed ID: 28093732
[TBL] [Abstract][Full Text] [Related]
7. The 2017 hormone therapy position statement of The North American Menopause Society.
Menopause; 2018 Nov; 25(11):1362-1387. PubMed ID: 30358733
[TBL] [Abstract][Full Text] [Related]
8. The 2017 hormone therapy position statement of The North American Menopause Society.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel
Menopause; 2017 Jul; 24(7):728-753. PubMed ID: 28650869
[TBL] [Abstract][Full Text] [Related]
9. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
10. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms.
NIH Consens State Sci Statements; 2005 Mar 21-23; 22(1):1-38. PubMed ID: 17308548
[TBL] [Abstract][Full Text] [Related]
11. Menopausal hormone therapy and women's health: An umbrella review.
Zhang GQ; Chen JL; Luo Y; Mathur MB; Anagnostis P; Nurmatov U; Talibov M; Zhang J; Hawrylowicz CM; Lumsden MA; Critchley H; Sheikh A; Lundbäck B; Lässer C; Kankaanranta H; Lee SH; Nwaru BI
PLoS Med; 2021 Aug; 18(8):e1003731. PubMed ID: 34339416
[TBL] [Abstract][Full Text] [Related]
12. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group.
Mendoza N; Ramírez I; de la Viuda E; Coronado P; Baquedano L; Llaneza P; Nieto V; Otero B; Sánchez-Méndez S; de Frutos VÁ; Andraca L; Barriga P; Benítez Z; Bombas T; Cancelo MJ; Cano A; Branco CC; Correa M; Doval JL; Fasero M; Fiol G; Garello NC; Genazzani AR; Gómez AI; Gómez MÁ; González S; Goulis DG; Guinot M; Hernández LR; Herrero S; Iglesias E; Jurado AR; Lete I; Lubián D; Martínez M; Nieto A; Nieto L; Palacios S; Pedreira M; Pérez-Campos E; Plá MJ; Presa J; Quereda F; Ribes M; Romero P; Roca B; Sánchez-Capilla A; Sánchez-Borrego R; Santaballa A; Santamaría A; Simoncini T; Tinahones F; Calaf J
Maturitas; 2022 Dec; 166():65-85. PubMed ID: 36081216
[TBL] [Abstract][Full Text] [Related]
13. Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause.
Davey DA
Womens Health (Lond); 2012 Mar; 8(2):169-89. PubMed ID: 22375720
[TBL] [Abstract][Full Text] [Related]
14. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2010 Mar; 17(2):242-55. PubMed ID: 20154637
[TBL] [Abstract][Full Text] [Related]
15. Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.
J Vis Exp; 2023 May; (195):. PubMed ID: 37235796
[TBL] [Abstract][Full Text] [Related]
16. No. 385-Indications for Pelvic Examination.
Evans D; Goldstein S; Loewy A; Altman AD
J Obstet Gynaecol Can; 2019 Aug; 41(8):1221-1234. PubMed ID: 31331610
[TBL] [Abstract][Full Text] [Related]
17. Long term hormone therapy for perimenopausal and postmenopausal women.
Marjoribanks J; Farquhar C; Roberts H; Lethaby A
Cochrane Database Syst Rev; 2012 Jul; (7):CD004143. PubMed ID: 22786488
[TBL] [Abstract][Full Text] [Related]
18. Menopausal hormone therapy and breast cancer.
Santen RJ
J Steroid Biochem Mol Biol; 2014 Jul; 142():52-61. PubMed ID: 23871991
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2007; 14(2):168-82. PubMed ID: 17259911
[TBL] [Abstract][Full Text] [Related]
20. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
